S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
S&P 500   3,829.34 (-2.45%)
DOW   31,402.01 (-1.75%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:THOR

Synthorx Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$67.99
0.00 (0.00 %)
(As of 01/23/2020)
Add
Compare
Today's Range
$67.99
Now: $67.99
$67.99
50-Day Range
$67.99
MA: $67.99
$67.99
52-Week Range
$11.05
Now: $67.99
$71.90
VolumeN/A
Average Volume474,507 shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Synthorx logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:THOR
CUSIP88517530
Phone858-750-4700
Employees48
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.72 per share

Profitability

Net Income$-56,610,000.00

Miscellaneous

Market Cap$2.20 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.98 out of 5 stars

Medical Sector

1025th out of 1,957 stocks

Pharmaceutical Preparations Industry

476th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthorx (NASDAQ:THOR) Frequently Asked Questions

What stocks does MarketBeat like better than Synthorx?

Wall Street analysts have given Synthorx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synthorx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Synthorx's earnings last quarter?

Synthorx, Inc. (NASDAQ:THOR) released its earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.12.
View Synthorx's earnings history
.

Who are Synthorx's key executives?

Synthorx's management team includes the following people:
  • Dr. Laura K. Shawver, CEO, Pres & Director (Age 62, Pay $606.48k)
  • Dr. Floyd E. Romesberg, Founder (Age 54, Pay $2.68k)
  • Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 57, Pay $457.71k)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 59, Pay $448.76k)
  • Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 44)

Who are some of Synthorx's key competitors?

What other stocks do shareholders of Synthorx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Lululemon Athletica (LULU), Micron Technology (MU) and Novartis (NVS).

When did Synthorx IPO?

(THOR) raised $100 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Synthorx's stock symbol?

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

What is Synthorx's stock price today?

One share of THOR stock can currently be purchased for approximately $67.99.

How much money does Synthorx make?

Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis.

How many employees does Synthorx have?

Synthorx employs 48 workers across the globe.

What is Synthorx's official website?

The official website for Synthorx is www.synthorx.com.

Where are Synthorx's headquarters?

Synthorx is headquartered at 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037.

How can I contact Synthorx?

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.